Ocuphire Pharma Investor Update

RM 16 Baseline Characteristics Study Eye Treatment and Placebo Arms Were Balanced Across Ocular Measures in the MIRA-3 Trial Baseline Characteristic Baseline Pupil Diameter Mean (mm) Max Dilated Pupil Diameter Mean (mm) Accommodation Mean (diopters) BCDVA letters 55 letters = 20/20 DCNVA letters 70 letters = 20/20 IOP (mmHg) Source: MIRA-3 Table 14.1.2.1 (ARP) (mITT). Nyxol n=248 5.1 7.2 7.4 57 65 16.2 Placebo n=120 4.9 7.1 7.6 57 65 16.1 Total n=368 5.1 7.2 7.5 57 65 16.1 Ocuphire PHARMA

View entire presentation